CD44 and breast carcinoma: Also, restoring and activating the PRL pathway was found to supress breast cancer stem-like cell (BCSC) subpopulations CD44+/CD24− and ALDH+ and reduced breast tumorigenesis in vitro and in vivo23,26,27.